Quarterly ResultMay 7, 2026, 04:37 PM
Whitehawk Therapeutics Q1 Net Loss $(22.2)M; Product Sales Zero
AI Summary
Whitehawk Therapeutics reported a net loss of $(22.2) million for Q1 2026, a significant decline from a net income of $73.0 million in Q1 2025, which included a large gain from the FYARRO Divestiture. Product sales were zero in Q1 2026 following the divestment of the FYARRO Business in March 2025. The company is now a clinical-stage oncology therapeutics company focused on its new portfolio of antibody drug conjugates, with research and development expenses increasing to $17.2 million.
Key Highlights
- Net loss was $(22.2) million in Q1 2026, compared to net income of $73.0 million in Q1 2025.
- Product sales were $0 in Q1 2026, down from $7.1 million in Q1 2025 due to the FYARRO Divestiture.
- Research and development expenses increased to $17.2 million in Q1 2026 from $8.8 million in Q1 2025.
- Selling, general and administrative expenses decreased to $6.3 million in Q1 2026 from $12.8 million in Q1 2025.
- Basic net loss per share was $(0.32) in Q1 2026, compared to basic net income per share of $1.84 in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $123.0 million as of March 31, 2026.
- Accumulated deficit grew to $375.4 million as of March 31, 2026.
- In-Process Research and Development (IPR&D) expense was $5.3 million in Q1 2026.
Price Impact
More from WHWK